Abstract
Correction to: British Journal of Cancer 2003; 89 (S1), S9–S11 doi:10.1038/sj.bjc.6601078
Unfortunately, due to an error, the tables were omitted from the above article.
All the three tables (Table 1 , 2 and 3 ) are reprinted below:
Table 1. Range of NICE guidance affecting patients with cancer.
| Technology appraisals |
|---|
| Drugs (Paclitaxel, Docetaxel, Trastuzumab, Vinorelbine, Topetecan, Caelyx, Temozolamide, Irintecan, Oxaliplatin, Raltitexed, Gemcitabine, Vinorelbine, Fludarabine, Imatinib) |
| Liquid-based cytology |
| Laparoscopic surgery for colorectal cancer |
| Clinical guidelines |
| Lung cancer |
| Familial breast cancer |
| Cancer service guidances |
| Breast, urology, haematico-oncological, colorectal, head and neck, child and adolescent, brain and cns, skin, supportive and palliative care |
| Cancer referral guidance |
| Confidential enquiries |
| Review of cancer care in acute units |
Table 2. Key principles underlying the Institute's clinical guidelines.
| NICE clinical guidelines should: |
| •aim to improve the quality of clinical care |
| •address the clinical effectiveness of treatments or management approaches (that is, how well treatments or management approaches work) |
| •address the cost effectiveness of treatments or management approaches |
| •be advisory |
| •be developed through a process that considers all those who might be affected by the guideline (usually including healthcare professionals, patients and their carers, service managers, the wider public, Government and the healthcare industries) |
| •be based on the best possible research evidence and professional consensus |
| •be developed using methods that command the respect of patients, the NHS and NHS stakeholders |
| •be developed with the involvement of patients and healthcare professionals |
| •set out the clinical care that might reasonably be expected throughout the NHS in England and Wales |
Table 3. The three versions of the clinical guideline.
| 1. NICE GUIDELINE (SHORT VERSION) |
| This uses a standard template, and contains: |
| •the Institute's guidance to the NHS |
| •implementation advice |
| •audit advice |
| •information on the expected impact on NHS resources |
| •a review date |
| •a clinical practice algorithm |
| •details of the Guideline Development Group members |
| 2. NATIONAL COLLABORATING CENTRE GUIDELINE (FULL VERSION) |
| This includes: |
| •the recommendations |
| •the profile of treatments and interventions assessed by the Guideline Development Group |
| •a description of how the evidence was collected, reviewed and assessed |
| •a description of how the recommendations were formulated and graded |
| •full reference details of the literature in the evidence base |
| •details of the Guideline Development Group members |
| •names of the stakeholders who commented on the first draft of the guideline |
| 3. INFORMATION FOR THE PUBLIC (PATIENT VERSION) |
| This version: |
| •interprets the recommendations made in the NICE Guideline for patients and carers |
| •aims to help patients to make informed choices about their care |
| •can be reproduced in patient/carer organisations’ own material, with the permission of the Institute |
The publisher would like to apologise for any inconvenience this error may have caused.